298 related articles for article (PubMed ID: 20832020)
1. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Chalmers AJ; Lakshman M; Chan N; Bristow RG
Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
[TBL] [Abstract][Full Text] [Related]
3. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
4. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
6. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
[TBL] [Abstract][Full Text] [Related]
7. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
Croset A; Cordelières FP; Berthault N; Buhler C; Sun JS; Quanz M; Dutreix M
Nucleic Acids Res; 2013 Aug; 41(15):7344-55. PubMed ID: 23761435
[TBL] [Abstract][Full Text] [Related]
9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Alotaibi M; Sharma K; Saleh T; Povirk LF; Hendrickson EA; Gewirtz DA
Radiat Res; 2016 Mar; 185(3):229-45. PubMed ID: 26934368
[TBL] [Abstract][Full Text] [Related]
11. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
14. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer.
Schlicker A; Peschke P; Bürkle A; Hahn EW; Kim JH
Int J Radiat Biol; 1999 Jan; 75(1):91-100. PubMed ID: 9972795
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: targeting PARP in cancer treatment.
Do K; Chen AP
Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis.
Noël G; Godon C; Fernet M; Giocanti N; Mégnin-Chanet F; Favaudon V
Mol Cancer Ther; 2006 Mar; 5(3):564-74. PubMed ID: 16546970
[TBL] [Abstract][Full Text] [Related]
18. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.
Soni A; Li F; Wang Y; Grabos M; Krieger LM; Chaudhary S; Hasan MSM; Ahmed M; Coleman CN; Teicher BA; Piekarz RL; Wang D; Iliakis GE
Mol Cancer Ther; 2018 Oct; 17(10):2206-2216. PubMed ID: 29970481
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.
Godon C; Cordelières FP; Biard D; Giocanti N; Mégnin-Chanet F; Hall J; Favaudon V
Nucleic Acids Res; 2008 Aug; 36(13):4454-64. PubMed ID: 18603595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
